MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

iRhythm Technologies Inc

Затворен

СекторЗдравеопазване

164.11 0.72

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

160.89

Максимум

165.56

Ключови измерители

By Trading Economics

Приходи

9M

-5.2M

Продажби

6.2M

193M

Марж на печалбата

-2.702

Служители

2,000

EBITDA

7.7M

2.4M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+36.16% upside

Дивиденти

By Dow Jones

Следващи печалби

19.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-484M

5.4B

Предишно отваряне

163.39

Предишно затваряне

164.11

Настроения в новините

By Acuity

50%

50%

174 / 360 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

iRhythm Technologies Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.01.2026 г., 21:55 ч. UTC

Печалби

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22.01.2026 г., 23:52 ч. UTC

Печалби

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22.01.2026 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22.01.2026 г., 23:40 ч. UTC

Пазарно говорене

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22.01.2026 г., 23:30 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.01.2026 г., 23:30 ч. UTC

Пазарно говорене

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22.01.2026 г., 22:37 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22.01.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

22.01.2026 г., 21:44 ч. UTC

Печалби

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22.01.2026 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22.01.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22.01.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22.01.2026 г., 21:30 ч. UTC

Печалби

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22.01.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Capital One To Acquire Brex >COF

22.01.2026 г., 21:13 ч. UTC

Печалби

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22.01.2026 г., 21:11 ч. UTC

Печалби

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22.01.2026 г., 21:11 ч. UTC

Печалби

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22.01.2026 г., 21:10 ч. UTC

Печалби

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22.01.2026 г., 21:06 ч. UTC

Печалби

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Rev $15.58B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q EPS $3.26 >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Net Interest Margin 8.26% >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Net $2.13B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Adj EPS $3.86 >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Capital One 4Q Net Charge-Offs $3.8B >COF

22.01.2026 г., 21:05 ч. UTC

Печалби

Intuitive Surgical 4Q EPS $2.21 >ISRG

Сравнение с други в отрасъла

Ценова промяна

iRhythm Technologies Inc Прогноза

Ценова цел

By TipRanks

36.16% нагоре

12-месечна прогноза

Среден 222.83 USD  36.16%

Висок 244 USD

Нисък 205 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за iRhythm Technologies Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

13

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

104.78 / 137.91Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

174 / 360 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
help-icon Live chat